Patrick Daly

DocwireNews

The human monoclonal antibody, dupilumab, inhibits the signaling of interleukin (IL)-4 and IL-13 to treat patients with asthma and other type-2 inflammatory diseases. However, according to a study by lead author Mohamed Sayed Zaazouee, reports are conflicting on the safety and efficacy of dupilumab. Thus, the study&rsquo;s authors performed a meta-analysis of dupilumab in patients with moderate-to-severe asthma and concluded that dupilumab was effective in this population and had minimal adverse events. Their evidence was presented in Frontiers in Pharmacology.After a systemic literature review, the researchers included 13 trials published to the PubMed, Embase, Scopus, Web of Science, Cochrane Library, and ClinicalTrials.gov databases by January 2022. Comparisons between <a href="https://medlineplus.gov/druginfo/meds/a617021.html" target="_blank" rel="noopener">dupilumab</a> and placebo at 12 and 24 weeks were retrieved and pooled for analyses using review manager 5.4.<h3>Dupilumab Appears Safe and Effective in Moderate-to-Severe Asthma</h3>Reportedly, dupilumab significantly improved forced expiratory volume in 1 second, asthma control questionnaire scores, fraction of exhaled nitric oxide levels, and immunoglobulin E levels at both week 12 and week 24 (P&lt;.05). In one study, dupilumab was associated with an increase in blood eosinophils at both time points, which the authors suggested may be due to a reduced dose of glucocorticoids in the dupilumab group compared with the placebo group.According to the authors, dupilumab had a significantly higher incidence of upper respiratory tract infection, injection-site reaction, and eosinophilia compared with placebo, but was comparable for all other adverse events. Researchers found these effects were independent of dosage as there were no significant differences between subgroups.The report acknowledged that heterogeneity of some outcomes across the included studies was the primary limitation of the analysis, which could have derived from some of the included studies enrolling asthmatic patients with other <a href="https://www.docwirenews.com/latest-pulmonology-news/asthma/asthma-associated-with-significantly-higher-risk-of-cardiovascular-disease-mortality/">type-2 inflammatory diseases</a>. The researchers also noted they were unable to conduct an age-dependent analysis of dupilumab.Overall, the authors supported the use of dupilumab, summarizing that, &ldquo;dupilumab improves pulmonary function and reduces local and systemic inflammatory markers with minimal adverse events in patients with moderate to severe asthma.&rdquo;Browse More <a href="https://www.docwirenews.com/asthma-resource-center/">Asthma and Pulmonology Research on DocWire News</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Dupilumab Safe and Effective at Treating Asthma

Asthma

The human monoclonal antibody, dupilumab, inhibits the signaling of interleukin (IL)-4 and IL-13 to treat patients with asthma and other type-2 inflammatory diseases. However, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe